Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/14/2017 08/15/2017 08/16/2017 08/17/2017 08/18/2017 Date
9.48(c) 9.38(c) 9.5(c) 9.45(c) 9.4(c) Last
1 568 455 845 380 745 893 798 278 1 164 297 Volume
+2.71% -1.05% +1.28% -0.53% -0.53% Change
More quotes
Financials ($)
Sales 2017 133 M
EBIT 2017 -75,8 M
Net income 2017 -83,4 M
Debt 2017 -
Yield 2017 -
Sales 2018 134 M
EBIT 2018 -62,6 M
Net income 2018 -70,2 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 5,96x
Capi. / Sales2018 5,93x
Capitalization 794 M
More Financials
Company
Spectrum Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products.It targets non-Hodgkin's lymphoma, advanced metastatic colorectal cancer, acute lymphoblastic leukemia, and multiple myeloma.It operates through... 
Sector
Biotechnology & Medical Research
Calendar
08/24 | 06:30pmPresentation
More about the company
Surperformance© ratings of Spectrum Pharmaceuticals,
Trading Rating : - Investor Rating :
More Ratings
Latest news on SPECTRUM PHARMACEUTICALS,
08/18 SPECTRUM PHARMACEUTICALS : (SPPI) Initiates Phase II Study for Cancer Drug
08/17 SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the 2017 Southern Cali..
08/16 CASI PHARMACEUTICALS : Reports Second Quarter 2017 Financial Results
08/15 SPECTRUM PHARMACEUTICALS : Announces Initiation of the Registrational Phase 3 Tr..
08/14 SPECTRUM PHARMACEUTICALS : Announces Initiation of the Registrational Phase 3 Tr..
08/04 SPECTRUM PHARMACEUTICALS, INC. (NASD : SPPI) Files An 8-K Entry into a Material ..
08/04 SPECTRUM PHARMACEUTICALS INC : Entry into a Material Definitive Agreement (form ..
08/03 SPECTRUM PHARMACEUTICALS : Reports Second Quarter 2017 Financial Results and Pip..
08/03 SPECTRUM PHARMACEUTICALS, INC. (NASD : SPPI) Files An 8-K Results of Operations ..
08/03 SPECTRUM PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fi..
More news
Sector news : Biotechnology & Medical Research - NEC
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
11:17aSpectrum Pharmaceuticals’ $SPPI Buy Rating Reiterated at HC Wainwright  
12:57aSpectrum Pharmaceuticals, Inc. $SPPI Receives Consensus Recommendation of “Bu.. 
08/19Louisiana State Employees Retirement System Has $215,000 Stake in Spectrum Ph.. 
08/18Investment Analysts’ Recent Ratings Changes for Spectrum Pharmaceuticals $SPP.. 
08/18Spectrum Pharmaceuticals downgraded by Zacks Investment Research to hold.  
More tweets
Qtime:35
News from SeekingAlpha
08/16 Premarket analyst action - healthcare
08/14 Spectrum's additional late-stage study of apaziquone in bladder cancer underw..
08/08 What To Expect After Spectrum Pharmaceuticals' Robust Earnings
08/04 Spectrum Pharmaceuticals' (SPPI) CEO Rajesh Shrotriya on Q2 2017 Results - Ea..
08/04 Spectrum Pharma Q2 beat propels shares, up 21%
Chart SPECTRUM PHARMACEUTICALS,
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Technical analysis trends SPECTRUM PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 11,5 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Rajesh C. Shrotriya Chairman & Chief Executive Officer
Joseph W. Turgeon President & Chief Operating Officer
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
Stuart Mitchell Krassner Independent Non-Employee Director
Luigi Lenaz Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SPECTRUM PHARMACEUTICALS, INC.112.19%794
INCYTE CORPORATION20.86%24 929
QUINTILES IMS HOLDINGS INC20.38%19 823
LONZA GROUP40.29%17 682
CELLTRION, INC.--.--%11 804
ALKERMES PLC-8.38%7 821